Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Establishment Of Five New Multiple Sclerosis Research Centres In Canada
The Multiple Sclerosis Society of Canada has made public the creation of five research and training centers with the participation of over one hundred established scientists and two hundred and fifty trainees. Funded entirely by the MS Society of Canada, which has already raised 32 million dollars from a goal of 60 million, the objectives of these new centers is to considerably increase the speed on MS research investigations so that an end to MS may be found as quickly as possible. These centres will serve as key establishments in achieving these goals.
generic viagra online
Thermo Scientific DNA Polymerases And Master Mixes Improve Yield And Specificity In PCR Amplifications
Thermo Fisher Scientific Inc., the world leader in serving science, announced it offers a premium collection of Thermo Scientific Taq DNA polymerases that are licensed and optimised for use in PCR processes. ThermoPrime Taq DNA Polymerase and Thermo-Start® Taq DNA Polymerase are designed to provide excellent amplification specificity and improved product yield. In addition, the high purity of these enzymes ensures their consistent and reliable performance.
News of the day
AMAG Pharmaceuticals Announces U.S. Launch Of Feraheme ™ (ferumoxytol) Injection
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced that Feraheme ™ (ferumoxytol) Injection is now available for commercial sale in the United States. Feraheme is an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease. Feraheme can provide patients with a 1 gram therapeutic course of iron in two 510 mg IV injections administered as quickly as 17 seconds each, within one week. Feraheme was approved by the U.S. Food and Drug Administration on June 30, 2009.
Mental Health

FDA Seeks Public Input On Transparency

The U.S. Food and Drug Administration will host a daylong meeting on June 24, 2009. During this meeting, the FDA will seek recommendations on how to make information on FDA activities and decision-making useful, understandable, and more accessible to the public. The meeting is scheduled for 8 a.m. to 5 p.m. EDT at the National Transportation Safety Board Conference Center, 429 L"Enfant Plaza, S.W., Washington, D.C., 20594. Please note there is no wireless service within the NTSB Conference Center. If you have questions, please e-mail them to Transparency.Meeting@fda.hhs.gov. Those who cannot attend the meeting can view the event via live Webcast at: http://www.fda.gov/transwebcast_june09. After the meeting, the Webcast will be available for viewing at the same link. For more information: June 3, 2009 Federal Register Notice FDA"s Transparency Task Force FDA"s Transparency Blog U.S. Food and Drug Administration


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009